Russ Conroy

Investigators are currently evaluating zavabresib plus ruxolitinib among patients with myelofibrosis in the phase 1 PROMise study.

Throughout 2026, CancerNetwork® and the journal ONCOLOGY® will be dedicated to sharing the most critical developments in the radiation oncology field.

According to the FDA, randomized trials are preferred when assessing MRD to support accelerated approvals in multiple myeloma.

Data from the phase 2 FIRM study support the preliminary potential of firmonertinib as frontline therapy in EGFR L858R-mutated NSCLC.

Safety data from the phase 1 LUMMICAR study 1 show no high-grade CRS or any-grade ICANS among patients with myeloma who received zevorcabtagene autoleucel.

Data from the phase 2 ALTER-L043 trial may support the viability of perioperative penpulimab-based treatment in resectable non–small cell lung cancer.

Data from CARTITUDE-4 show that cilta-cel can improve outcomes for patients with lenalidomide-refractory multiple myeloma as early as first relapse.

The FDA has assigned a PDUFA date of August 30, 2026, for approving ropeginterferon alfa-2b-njft among adults with essential thrombocytopenia.

Data from the phase 3 MajesTEC-9 trial support teclistamab as an essential therapy for patients with multiple myeloma as early as first relapse.

Data from the QUILT-3.055 and QUILT-2.023 studies support the accelerated approval of the nogapendekin alfa inbakicept regimens in Saudi Arabia.

Investigators will submit detailed results from the QUILT-2.023 and QUILT-3.055 trials for peer-reviewed publication and future scientific presentations.

Data from the phase 1/2 EVICTION study support the breakthrough therapy designation for ICT01 plus venetoclax/azacitidine in acute myeloid leukemia.

Osimertinib plus chemotherapy improved overall survival across various subgroups in the phase 3 FLAURA2 trial, including those with CNS metastases.

Data from the phase 3 HARMONi trial support the application for the ivonescimab regimen in this EGFR-mutated NSCLC population.

The FDA no longer considers the phase 3 ALLELE trial adequate to support the approval of tabelecleucel for patients with EBV-positive PTLD.

The safety profile of atezolizumab plus bevacizumab and chemotherapy in this phase 3 trial was comparable with prior reports of the agents.

Data from a phase 1/2a trial show no dose-limiting toxicities associated with ELC-100 among patients with neuroendocrine tumors.

Early data from the ABC-HCC trial showed an improvement in median time to failure of strategy with atezolizumab/bevacizumab vs TACE in this HCC population.

Supporting data for zoldonrasib’s breakthrough therapy designation in NSCLC came from the phase 1 RMC-9805-001 trial.

Investigators will assess the safety and early activity of OTP-01 among patients in the US and Australia across approximately 20 centers.

Data from the CRITICS-II trial support total neoadjuvant chemotherapy plus chemoradiotherapy as a preferred candidate for future study in this population.

Neoadjuvant immunotherapy plus chemotherapy did not definitively increase the risk of severe pneumonitis compared with adjuvant immunotherapy.

Clearance of the investigational new drug application allows investigators to expand their assessment of KLN-1010 as part of the phase 1 inMMyCAR trial.

Prior data from the 2025 ASH meeting showed that CK0804 may complement JAK inhibition among patients with myelofibrosis.

The randomized KANDLELIT-007 trial will enroll approximately 675 patients with advanced non–small cell lung cancer across the world.

Investigators are currently assessing treatment with Alpha DaRT among those with recurrent CSCC as part of the ReSTART trial.

Developers intend to submit a supplemental biologics license application for tafasitamab plus lenalidomide and R-CHOP in this DLBCL population.

Data from the IZALCO trial support the use of subcutaneous on-body injector administration of an isatuximab-based regimen in relapsed/refractory multiple myeloma.

Overall survival significantly improved with radiation plus cisplatin/paclitaxel in the phase 2 RTOG 9911 trial over a historical control cohort.

Sorafenib improved the median progression-free survival compared with placebo among patients with metastatic uveal melanoma in the STREAM study.